What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?

被引：0
|
作者：
Weiss, R. [1 ]
Griffin, M. L. [1 ]
机构：
[1] Harvard Med Sch, Psychiat Div Alcohol Drugs & Addict, McLean Hosp, Belmont, MA USA
来源：
EUROPEAN PSYCHIATRY | 2023年 / 66卷
关键词：
D O I：
10.1192/j.eurpsy.2023.1196
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EPP0916
引用
下载
收藏
页码：S569 / S570
页数：2
相关论文
共 50 条
  • [31] Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States
    Saha, Tulshi D.
    Kerridge, Bradley T.
    Goldstein, Rise B.
    Chou, S. Patricia
    Zhang, Haitao
    Jung, Jeesun
    Pickering, Roger P.
    Ruan, W. June
    Smith, Sharon M.
    Huang, Boji
    Hasin, Deborah S.
    Grant, Bridget F.
    JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 (06) : 772 - 780
  • [32] Naloxone prescription fills and use by patients treated for opioid use disorder by telehealth
    Weiner, Scott G.
    Miller, Emily N.
    Burke, Barbara
    Clear, Brian
    DRUG AND ALCOHOL DEPENDENCE REPORTS, 2024, 11
  • [33] Prescription Opioid Use Disorder Among Adults Reporting Prescription Opioid Use With or Without Misuse in the United States
    Han, Beth
    Jones, Christopher M.
    Einstein, Emily B.
    Dowell, Deborah
    Compton, Wilson M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2024, 85 (03)
  • [34] Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment
    Jens Reimer
    Tobias Vogelmann
    Daniel Trümper
    Norbert Scherbaum
    Substance Abuse Treatment, Prevention, and Policy, 14
  • [35] Opioid use disorder and overdose among youth following an initial opioid prescription
    Hadland, Scott E.
    Bagley, Sarah M.
    Gai, Mam Jarra
    Earlywine, Joel J.
    Schoenberger, Samantha F.
    Morgan, Jake R.
    Barocas, Joshua A.
    ADDICTION, 2021, 116 (10) : 2790 - 2800
  • [36] Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment
    Reimer, Jens
    Vogelmann, Tobias
    Truemper, Daniel
    Scherbaum, Norbert
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2019, 14 (01)
  • [37] Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment
    Pagare, Piyusha P.
    Obeng, Samuel
    Huang, Boshi
    Marcus, Madison M.
    Nicholson, Katherine L.
    Townsend, Andrew E.
    Banks, Matthew L.
    Zhang, Yan
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, : 1197 - 1209
  • [38] Opioid agonist therapy as treatment for opioid use disorder: Comparing duration, risks and frequency of healthcare encounters
    Tourchian, Nima
    Tadrous, Mina
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 276 - 277
  • [39] Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients
    Muriel, Javier
    Margarit, Cesar
    Barrachina, Jordi
    Ballester, Pura
    Flor, Andrea
    Morales, Domingo
    Horga, Jose F.
    Fernandez, Eduardo
    Peiro, Ana M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (04) : 439 - 448
  • [40] Alcohol use in opioid agonist treatment
    Nolan S.
    Klimas J.
    Wood E.
    Addiction Science & Clinical Practice, 11 (1)
12345